table of content
1 Introduction to Research & Analysis Reports
1.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Overall Market Size
2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size: 2022 VS 2030
2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players in Global Market
3.2 Top Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies Ranked by Revenue
3.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Companies
3.4 Top 3 and Top 5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players in Global Market
3.6.1 List of Global Tier 1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Markets, 2022 & 2030
4.1.2 Single-stranded AAV (ssAAV)
4.1.3 Self-complementary AAV (scAAV)
4.2 By Type - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue & Forecasts
4.2.1 By Type - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2023
4.2.2 By Type - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2024-2030
4.2.3 By Type - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2022 & 2030
5.1.2 Hemophilia
5.1.3 Ophthalmology
5.1.4 Lysosomal Storage Disorders
5.1.5 Neurological Disorders
5.1.6 Others
5.2 By Application - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue & Forecasts
5.2.1 By Application - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2023
5.2.2 By Application - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2024-2030
5.2.3 By Application - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2022 & 2030
6.2 By Region - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue & Forecasts
6.2.1 By Region - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2023
6.2.2 By Region - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2024-2030
6.2.3 By Region - Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2030
6.3.2 US Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.3.3 Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.3.4 Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2030
6.4.2 Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4.3 France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4.4 U.K. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4.5 Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4.6 Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4.7 Nordic Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.4.8 Benelux Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2030
6.5.2 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.5.3 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.5.4 South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.5.5 Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.5.6 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2030
6.6.2 Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.6.3 Argentina Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, 2018-2030
6.7.2 Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.7.3 Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.7.4 Saudi Arabia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
6.7.5 UAE Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, 2018-2030
7 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies Profiles
7.1 BioMarin Pharmaceutical
7.1.1 BioMarin Pharmaceutical Company Summary
7.1.2 BioMarin Pharmaceutical Business Overview
7.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.1.4 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.1.5 BioMarin Pharmaceutical Key News & Latest Developments
7.2 Sangamo Therapeutics
7.2.1 Sangamo Therapeutics Company Summary
7.2.2 Sangamo Therapeutics Business Overview
7.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.2.4 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.2.5 Sangamo Therapeutics Key News & Latest Developments
7.3 Amicus Therapeutics
7.3.1 Amicus Therapeutics Company Summary
7.3.2 Amicus Therapeutics Business Overview
7.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.3.4 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.3.5 Amicus Therapeutics Key News & Latest Developments
7.4 Roche
7.4.1 Roche Company Summary
7.4.2 Roche Business Overview
7.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.4.4 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.4.5 Roche Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.5.4 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 NightstaRx
7.6.1 NightstaRx Company Summary
7.6.2 NightstaRx Business Overview
7.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.6.4 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.6.5 NightstaRx Key News & Latest Developments
7.7 MeiraGTx
7.7.1 MeiraGTx Company Summary
7.7.2 MeiraGTx Business Overview
7.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.7.4 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.7.5 MeiraGTx Key News & Latest Developments
7.8 Sarepta Therapeutics
7.8.1 Sarepta Therapeutics Company Summary
7.8.2 Sarepta Therapeutics Business Overview
7.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.8.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.8.5 Sarepta Therapeutics Key News & Latest Developments
7.9 Neurocrine Biosciences
7.9.1 Neurocrine Biosciences Company Summary
7.9.2 Neurocrine Biosciences Business Overview
7.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.9.4 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.9.5 Neurocrine Biosciences Key News & Latest Developments
7.10 Voyager Therapeutics
7.10.1 Voyager Therapeutics Company Summary
7.10.2 Voyager Therapeutics Business Overview
7.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.10.4 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.10.5 Voyager Therapeutics Key News & Latest Developments
7.11 Asklepios Biopharmaceutical
7.11.1 Asklepios Biopharmaceutical Company Summary
7.11.2 Asklepios Biopharmaceutical Business Overview
7.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Product Offerings
7.11.4 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in Global Market (2018-2023)
7.11.5 Asklepios Biopharmaceutical Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
